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Available online 11 October 2011Abstract Human induced pluripotent stem (hiPS) cells have potential uses for drug discovery and cell therapy, including
generation of pancreatic β-cells for diabetes research and treatment. In this study, we developed a simple protocol for gen-
erating insulin-producing cells from hiPS cells. Treatment with activin A and a GSK3β inhibitor enhanced efficient endoder-
mal differentiation, and then combined treatment with retinoic acid, a bone morphogenic protein inhibitor, and a
transforming growth factor-β (TGF-β) inhibitor induced efficient differentiation of pancreatic progenitor cells from defin-
itive endoderm. Expression of the pancreatic progenitor markers PDX1 and NGN3 was significantly increased at this step and
most cells were positive for anti-PDX1 antibody. Moreover, several compounds, including forskolin, dexamethasone, and a
TGF-β inhibitor, were found to induce the differentiation of insulin-producing cells from pancreatic progenitor cells. By
combined treatment with these compounds, more than 10% of the cells became insulin positive. The differentiated cells se-
creted human c-peptide in response to various insulin secretagogues. In addition, all five hiPS cell lines that we examined
showed efficient differentiation into insulin-producing cells with this protocol.
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doi:10.1016/j.scr.2011.10.002defined transcription factors (Takahashi et al., 2007; Yu et
al., 2007; Nakagawa et al., 2008). Since hiPS cells are able
to proliferate indefinitely and can differentiate into many
cell types, they have great potential for use in drug discover-
y and cell therapy. One possible application of hiPS cells is
the generation of pancreatic β-cells for research and treat-
ment of type 1 diabetes, an autoimmune disease that results
from destruction of insulin-producing β-cells in the pancre-
as. Islet transplantation can be an effective therapy for
type 1 diabetes, but the shortage of donors limits its clinical
application on a large scale. One possible way to overcome
the shortage of pancreatic islets is the generation of
insulin-producing cells from human pluripotent stem cells,
275Insulin-producing cells from hiPS cellssuch as hiPS cells or human embryonic stem (hES) cells.
Insulin-producing cells derived from hiPS or hES cells could
also be useful for identifying novel targets for the develop-
ment of antidiabetic drugs.
There have already been several reports on the genera-
tion of insulin-producing cells from hiPS cells or hES cells in
vitro (D'Amour et al., 2006; Kroon et al., 2008; Jiang et al.,
2007; Tateishi et al., 2008; Zhang et al., 2009; Maehr et
al., 2009; Chen et al., 2009; Assady et al., 2001; Phillips et
al., 2007). For example, stepwise protocols have been de-
veloped to achieve differentiation of hiPS or hES cells into
insulin-producing cells by mimicking the process of pancre-
atic development (D'Amour et al., 2006; Kroon et al., 2008;
Jiang et al., 2007; Tateishi et al., 2008; Zhang et al.,
2009). A protocol utilizing small molecules to induce pancre-
atic differentiation has also been described (Chen et al.,
2009). In addition, it has been demonstrated that hES-
derived insulin-producing cells can reduce the serum glucose
level in diabetic mice (Kroon et al., 2008). These studies
have demonstrated that hiPS cells or hES cells can be differ-
entiated into insulin-producing cells that might function in
vivo.
During the generation of insulin-producing cells from hiPS
or hES cells, the process of deriving PDX1-positive pancreatic
progenitors from definitive endoderm, which gives rise to
the pancreas, seems to be a critical step. Although several
methods of differentiating hES or hiPS cells into definitive en-
doderm have already been reported (D'Amour et al., 2006;
Jiang et al., 2007; Maehr et al., 2009; D'Amour et al., 2005;
Borowiak et al., 2009), deriving pancreatic progenitors from
definitive endoderm is still a challenge. The process by
which PDX1-positive cells undergo differentiation into
insulin-producing cells seems to be another key step. Howev-
er, the mechanisms involved are largely unknown. Several
methods for inducing efficient differentiation of definitive en-
doderm into PDX1-positive cells have recently been reported
(Chen et al., 2009; Cai et al., 2010; Ameri et al., 2010;
Johannesson et al., 2009), but the culture conditions for in-
duction of these cells and their differentiation into insulin-
producing cells remain to be optimized.
In this study, we developed a simple stepwise protocol for
generating insulin-producing cells from hiPS cells. Combined
treatment with small molecules induced the efficient differ-
entiation into pancreatic progenitor cells and insulin-
producing cells. With this new protocol, multiple hiPS cell
lines generated from different donors showed differentia-
tion into insulin-producing cells at a similar level of
efficiency.Results
Differentiation of hiPS cells into definitive endoderm
First, we developed a method for generating definitive
endoderm, a germ cell layer that gives rise to the pancreas,
from hiPS cells. The 253G1 hiPS cell line (Nakagawa et al.,
2008), which was generated from human fibroblasts by over-
expression of OCT3/4, SOX2, and KLF4, was used. It has been
reported that treatment with activin A and Wnt 3a under low
serum conditions induces differentiation of human ES cells
into endoderm (D'Amour et al., 2006), so we adapted thismethod for hiPS cells with slight modifications (Fig. 1A).
After incubating hiPS cells with activin A and Wnt 3a for
24 h, the cells were subsequently incubated with activin A
alone for an additional two days. Expression of the endoder-
mal markers SOX17 and FOXA2 increased significantly
(Fig. 1B), and immunostaining showed that 41.4±22.3% of
total cells had differentiated into SOX17 and FOXA2
double-positive cells in seven independent experiments
(Fig. 1C and Fig. S1). Fewer SOX17 and FOXA2 double-
positive cells appeared in control cultures that were not trea-
ted with any factors or cultures treated with activin A alone
(3.0±6.1% and 21.9±20.8% of total cells in seven independent
experiments, respectively) (Fig. 1C and Fig. S1).
Some of the effects of Wnt/β-catenin signaling are known
to be mimicked by inhibition of GSK3β activity (Doble and
Woodgett, 2003), and we found that the GSK3β-specific in-
hibitor CHIR99021 could be used to induce the differentia-
tion of endoderm instead of Wnt 3a. Combined treatment
with activin A and CHIR99021 induced expression of SOX17
and FOXA2 (Fig. 1B), and most of the cells were double-
positive for SOX17 and FOXA2 antibodies (74.8±6.7% in
seven independent experiments) (Fig. 1C and Fig. S1).
These findings suggested that combined treatment with
activin A and CHIR99021 could induce efficient differentia-
tion of hiPS cells into definitive endoderm.Pancreatic differentiation from definitive endoderm
Several groups have shown that Noggin, an endogenous an-
tagonist of BMP signaling, and retinoic acid induce pancreat-
ic differentiation of definitive endoderm (Kroon et al., 2008;
Jiang et al., 2007; Zhang et al., 2009; Cai et al., 2010;
Johannesson et al., 2009; Ostrom et al., 2008; Micallef et
al., 2005; Stafford et al., 2006). To examine the effect of
these factors, we treated hiPS-derived definitive endoderm
with Noggin, retinoic acid, and both agents together
(Fig. 2A). When cells were cultured with Noggin or retinoic
acid alone for seven days, the yield of PDX1-positive cells
was relatively low (Fig. 2B). On the other hand, combined
treatment with Noggin and retinoic acid significantly in-
creased the yield of PDX1-positive cells to 42.6±9.3% in
three independent experiments (Fig. 2B).
Dorsomorphin inhibits BMP type I receptors (ALK2, ALK3,
and ALK6) and thus blocks BMP signaling (Yu et al., 2008).
We found that dorsomorphin could be used for induction of
pancreatic differentiation in this culture system instead of
Noggin (Fig. 2A). Treatment with dorsomorphin alone had
no influence on the yield of PDX1-positive cells, but the com-
bination of dorsomorphin and retinoic acid increased the
yield of PDX1-positive cells to the same extent as treatment
with Noggin and retinoic acid (50.5±8.2% in five indepen-
dent experiments) (Fig. 2B). Since dorsomorphin was
expected to be more stable than Noggin, we used it instead
of Noggin in the following experiments.
Next, we examined the expression of other pancreatic
markers under these culture conditions. While the expres-
sion of PDX1, HNF6, and HLXB9 was increased by treatment
with dorsomorphin and retinoic acid, expression of the pan-
creatic endocrine progenitor marker NGN3 was not detected
(Fig. 2C). Since induction of pancreatic endocrine progenitor
cells seemed to be inadequate, we screened for small
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Figure 1 Differentiation of hiPS cells into definitive endoderm. (A) Scheme for inducing differentiation into definitive endoderm.
(B) hiPS cells were treated with the indicated factors for three days as shown in A. Expression of SOX17 and FOXA2was analyzed by quan-
titative RT-PCR on day 3. The Y-axis indicates the relative change of mRNA expression compared with that by control cells (no factors
added). The average of eight independent experiments is shown. Error bars indicate s.d. (C) Cells were immunostained with SOX17 and
FOXA2 antibodies on day 3. Scale bar=100 μm. Ctrl, control (no factors added); Act, activin A; Wnt, Wnt 3a; CHIR, CHIR99021.
276 Y. Kunisada et al.molecules that induced the NGN3 expression in the presence
of dorsomorphin and retinoic acid from among various com-
pounds known to regulate stem cell differentiation (Table
S1). As a result, a TGF-β type I receptor inhibitor
(SB431542) was found to induce NGN3 expression in combi-
nation with dorsomorphin and retinoic acid (Fig. 2C). Treat-
ment with dorsomorphin, retinoic acid, and SB431542 not
only increased the expression of NGN3, but also the expres-
sion of other pancreatic markers, such as NEUROD1, PDX1,
SOX9, and HLXB9 (Fig. 2C). Furthermore, treatment with
these three compounds increased the percentage of PDX1-
positive cells to 71.9±9.7% in five independent experiments
(Fig. 2B). In contrast, incubation with SB431542 alone had no
effect on the expression of PDX1 and NGN3 mRNA or the ex-
pression of PDX1 protein (Figs. 2B, C). Other TGF-β type I re-
ceptor inhibitors, such as Alk5 inhibitor II, A-83-01, and TGF-
β RI inhibitor VIII, also induced NGN3 expression incombination with dorsomorphin and retinoic acid (Fig. S2),
indicating that differentiation into pancreatic endocrine
progenitor cells was enhanced by blockade of TGF-β signal-
ing. Thus, the combination of dorsomorphin, retinoic acid,
and SB431542 efficiently induced pancreatic differentiation
from definitive endoderm.
To investigate whether PDX1-positive cells could be dif-
ferentiated into insulin-producing cells, we continued to cul-
ture PDX1-positive cells after withdrawal of the above three
compounds, and found that insulin (INS) and C-peptide
double-positive cells emerged after eight days (Fig. 3A and
Fig. S3). In this subpopulation of cells, INS expression in-
creased significantly over time (Fig. 3B). In contrast, cells
treated with each compound alone or any other combination
of compounds showed little differentiation into insulin-
producing cells (Figs. 3A, B, Fig. S3, and data not shown).
These results supported the concept that the combination
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percentage of PDX1-positive cells in 3–5 independent experiments is shown. Scale bar=100 μm. (C) Cells were treated with the
indicated factors on day 3. Expression of NGN3, NEUROD1, PDX1, HNF6, HLXB9, and SOX9 was analyzed by quantitative RT-PCR on
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277Insulin-producing cells from hiPS cellsof dorsomorphin, retinoic acid, and SB431542 achieved effi-
cient commitment to differentiation into pancreatic cells.Enhancement of pancreatic progenitor cell differen-
tiation into insulin-producing cells
Although insulin-producing cells were detected in the cul-
tures treated with dorsomorphin, retinoic acid, and
SB431542, the percentage of such cells was very low. This
suggested that additional signals were necessary forefficient induction of insulin-producing cells from PDX1-
positive cells. To enhance the differentiation of insulin-
producing cells, we screened for small molecules that in-
creased INS expression by PDX1-positive pancreatic progenitor
cells after day 10 from among various compounds known to
regulate stem cells differentiation (Fig. 4A and Table S1). As
a result, forskolin, dexamethasone, and Alk5 inhibitor II were
found to increase INS expression (Fig. 4B). Immunostaining
and FACS analysis showed that insulin-producing cells were in-
creased in cultures treated with forskolin, dexamethasone, or
Alk5 inhibitor II (Figs. 4C, D).
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Figure 3 Differentiation into insulin-producing cells. (A) Cells were treated with the indicated factors from day 3 to day 10. After
removal of the factors on day 10, the cells were cultured further and immunostained with insulin and C-peptide antibodies on day
18. Scale bar=100 μm. A typical example of C-peptide and insulin double-positive cells is highlighted. (B) Expression of INS was ana-
lyzed by quantitative RT-PCR on days 10–18. The Y-axis indicates the relative change of mRNA expression compared with that by
cells on day 3. Error bars indicate s.d. The results are representative of three independent experiments. Ctrl, control (no factors
added); SB, SB431542; DM, dorsomorphin; RA, retinoic acid; Cpep, C-peptide; INS, insulin; Hoe, Hoechst.
278 Y. Kunisada et al.Forskolin is an adenylate cyclase activator that increases
the intracellular cyclic AMP (cAMP) level, suggesting that an
increment of intracellular cAMP might enhance differentia-
tion of pancreatic endocrine progenitor cells into insulin-
producing cells. To verify this hypothesis, we treated PDX1-
positive cells with the phosphodiesterase inhibitor
3-isobutyl-1-methylxanthine (IBMX) and the cAMP analog
dibutyryl cyclic AMP (dbcAMP). We found that IBMX and
dbcAMP increased INS expression and the population of
insulin-positive cells, as did forskolin (Fig. S4A, B), suggest-
ing that a high intracellular cAMP level contributed to the
differentiation of PDX1-positive cells into insulin-producing
cells. On the other hand, Alk5 inhibitor II and other TGF-β
type I receptor inhibitors (including A-83-01, SB431542, and
TGF-β RI inhibitor VIII) also increased INS expression and the
number of insulin-positive cells (Fig. S4A, B), suggesting that
differentiation into insulin-producing cells could be enhanced
by blocking endogenous TGF-β.
To examine the additive effect of forskolin, dexametha-
sone, and Alk5 inhibitor II on differentiation into insulin-
producing cells, we cultured PDX1-positive cells with a combi-
nation of these compounds. We also added nicotinamide,
which has been reported to induce differentiation of pancre-
atic β-cells (Sjoholm et al., 1994; Otonkoski et al., 1993).
While incubation with nicotinamide alone had no effect on
INS expression and the number of insulin-positive cells under
these culture conditions, it slightly increased the intensity
of staining with insulin antibody for the cells treated with
three compounds (forskolin, dexamethasone, and Alk5 inhibi-
tor II) (Figs. 4B–D and data not shown). The level of INS ex-
pression and the yield of C-peptide-positive cells amongcells treated with all four agents (forskolin, dexamethasone,
Alk5 inhibitor II, and nicotinamide) were similar to those for
the cells treated with forskolin alone (Figs. 4B, D). However,
these cells were more tightly attached to the plates and
grew at a higher density than cells treated with forskolin
alone (Fig. 4C). Therefore, we used this combination in the
following experiment. FACS analysis showed that 7.8% of the
cultured cells were C-peptide-positive glucagon-negative
cells and 2.0% of the cells were C-peptide-positive glucagon-
negative cells (Fig. 4D). The average percentage of insulin-
positive cells obtained in seven independent experiments
was 11.8% (range: 8.0−16.9%, data not shown).
Immunostaining demonstrated that most of the insulin-
positive or C-peptide positive cells were also positive for an-
tibodies to various islet-enriched transcription factors, in-
cluding PDX1, NEUROD1, ISLET-1, PAX6, and NKX2.2
(Fig. 5A and Fig. S5), a finding that matched the process of
pancreatic development (Oliver-Krasinski and Stoffers,
2008). Under this culture condition, other types of pancreat-
ic endocrine cells expressing glucagon (GCG), ghrelin, or so-
matostatin were also identified (Fig. 5A), but pancreatic
polypeptide-positive cells were not detected (data not
shown). Some of the glucagon- or somatostatin-positive
cells were also stained by insulin antibody, whereas most
of the ghrelin-positive cells were negative for it.Pharmacological stimulation of insulin secretion
To examine the functionality of hiPS-derived insulin-positive
cells, we measured the C-peptide level in the culture
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Figure 4 Small molecules inducing differentiation into insulin-producing cells. (A) Scheme for inducing differentiation into insulin-
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279Insulin-producing cells from hiPS cellsmedium after incubation with glucose or insulin secreta-
gogues. Insulin-producing cells that had been induced by
treatment with the four compounds (forskolin, dexametha-
sone, Alk5 inhibitor II, and nicotinamide) were utilized for
these experiments. While incubation with glucose did not
alter insulin secretion, treatment with tolbutamide (a KATP
channel blocker), (−)-Bay K8644 (a L-type Ca2+ channelagonist), carbachol (a muscarinic agonist), IBMX (a phospho-
diesterase inhibitor), and potassium chloride (a depolarizing
agent) increased c-peptide release (Fig. 5B). These results
suggested that the cells were able to secrete c-peptide in re-
sponse to various stimuli, but had not differentiated into
fully mature β-cells with the ability to secrete insulin in re-
sponse to glucose stimulation.
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Figure 5 Characterization of insulin-producing cells derived from hiPS cells. (A) Cells were treated with the four compounds (forskolin,
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IBMX, or 30 mM potassium chloride (KCl). Error bars indicate s.d. *Pb0.01 by Student's t-test. The results are representative of three in-
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280 Y. Kunisada et al.Differentiation of multiple hiPS cell lines into
insulin-producing cells
We used the 253G1 hiPS cell line to develop the present
protocol. To examine whether this protocol was also effec-
tive for promoting the differentiation of other hiPS cell
lines, we tested four more hiPS cell lines, which were
1503-iPS (297A1), 1392-iPS (297F1), NHDF-iPS (297L1), and
201B7. While 201B7 was generated from dermal fibroblasts
of the same donor as 253G1 by overexpression of OCT4,
KLF4, SOX2, and C-MYC (Takahashi et al., 2007), the other
cell lines (1503-iPS (297A1), 1392-iPS (297F1), and NHDF-
iPS (297L1)) were generated from the fibroblasts ofdifferent donors by overexpression of the same genes (Taka-
hashi et al., 2009). When the cells were treated with activin
A and CHIR99021 as described above, a high yield of SOX17-
and FOXA2 double-positive cells was obtained from all four
of the hiPS cell lines tested (Fig. S6). After treatment with
the various compounds described above, these cells under-
went differentiation into PDX1-positive cells (Fig. S7) and
then finally into insulin-positive cells at a similar level of ef-
ficiency (Fig. 5C). FACS analysis showed that insulin-
positive cells accounted for 15.8% (range: 14.7–17.7%),
11.6% (range: 8.3–14.0%), 12.3% (range: 3.9–17.7%), and
9.2% (range: 7.1–10.6%) of the total cells in cultures of
1503-iPS, (297A1), 1392-iPS (297F1), NHDF-iPS (297L1),
281Insulin-producing cells from hiPS cellsand 201B7, respectively, in four independent experiments.
These findings suggested that our method can be applied
to induce the efficient differentiation of pancreatic cells
from various hiPS cell lines.
Discussion
In this study, we developed a simple protocol for inducing
the differentiation of human iPS cells into insulin-producing
cells. With this method, most iPS cells underwent differenti-
ation into SOX17and FOXA2 double-positive definitive endo-
derm, and then into PDX1-positive pancreatic progenitor
cells. Finally, after treatment with a combination of low mo-
lecular weight compounds, differentiation into insulin-
producing cells was achieved at a yield of more than 10%.
Our protocol does not include complicated processes, such
as embryoid body formation, cell sorting by FACS, and re-
seeding into other plates. While we used activin A and
fetal bovine serum (FBS) during early differentiation, each
step of differentiation was mainly induced by small mole-
cules, making the differentiation process efficient and
stable.
As the first step of our method, hiPS cells underwent dif-
ferentiation into definitive endoderm by treatment with
activin A and the GSK3β inhibitor CHIR99021. In other
methods, activin A and Wnt 3a have mainly been used to in-
duce definitive endoderm (D'Amour et al., 2006; Kroon et
al., 2008; Maehr et al., 2009; Chen et al., 2009; Ameri et
al.; Johannesson et al., 2009). However, we found that
treatment with activin A plus CHIR99021 induced SOX17
and FOXA2 double-positive definitive endoderm more effi-
ciently compared with activin A plus Wnt 3a. We confirmed
that CHIR99021 was a highly selective inhibitor of GSK3β and
GSK3α by the kinase profiling assay (KinaseAdvisor™, Caliper
LifeSciences) (data not shown), suggesting that its influence
on other signaling processes would be very small. In consider-
ation of efficiency, stability, and cost, using CHIR99021 in-
stead of Wnt 3a is preferable for inducing differentiation into
definitive endoderm.
Next, we induced differentiation of definitive endoderm
into pancreatic progenitor cells. A large number of factors,
including Cyclopamine-KAAD, (−)-indolactam V, Noggin,
retinoic acid, FGF2, FGF4, FGF10, and EGF, have been
reported to induce the differentiation of pancreatic progen-
itor cells (D'Amour et al., 2006; Kroon et al., 2008; Jiang et
al., 2007; Chen et al., 2009; Cai et al.; Ameri et al.; Johan-
nesson et al., 2009). Among these factors, we found com-
bined treatment with Noggin and retinoic acid was
effective for inducing PDX1-positive cells in our culture con-
dition. We also showed that treatment with the BMP recep-
tor inhibitor dorsomorphin and retinoic acid could induce
the differentiation of PDX1-positive cells. This finding is con-
sistent with several recent reports that Noggin can be
replaced by dorsomorphin in the induction of ES cell differ-
entiation (Hao et al., 2008; Wada et al., 2009; Nostro et
al., 2011). Because of its superior stability and lower cost,
dorsomorphin seemed to be a better choice than Noggin for
induction of PDX1-positive cells. Furthermore, we found
that inhibitors of the TGF-β type I receptor were effective
for inducing pancreatic differentiation in combination with
retinoic acid and dorsomorphin. This is consistent with a re-
cent report that PDX1 expression was induced by treatmentof mouse embryos with SB431542 at the 5–6 somite stage
(Wandzioch and Zaret, 2009). Moreover, while we were pre-
paring this manuscript, Rezania et al. and Nostro et al.
reported that treatment with TGF-β type I receptor inhibitors
following pancreatic specification induced the differentiation
into pancreatic endocrine cells from human ES cells (Nostro
et al., 2011; Rezania et al.). Our results were also consistent
with their reports. Thus, TGF-β signaling might have a neg-
ative influence on differentiation into pancreatic progeni-
tor cells.
As the next step, we investigated conditions that allowed
the efficient generation of insulin-producing cells from
PDX1-positive cells. Various compounds, including forskolin,
dbcAMP, IBMX, TGF-β type I receptor inhibitors, and dexa-
methasone, have been found to increase the number of
insulin-producing cells. Since forskolin and IBMX are known
to increase the intracellular cAMP level and dbcAMP is a
cell-permeable cAMP analog, it is suggested that the cellular
cAMP level is one of the key factors regulating the differen-
tiation of insulin-producing cells. However, we found that
long-term exposure (N20 days) to forskolin alone decreased
the number of insulin-producing cells (data not shown).
Thus, a high level of cAMP might be needed in priming for
differentiation, but excess cAMP might have a negative ef-
fect on the survival of insulin-producing cells. Interestingly,
when cells were treated with dexamethasone in addition to
forskolin, the number of insulin-producing cells remained
stable for a long period. The precise mechanism remains to
be analyzed, but this finding indicates that glucocorticoid
signaling promotes the survival of insulin-producing cells.
TGF-β type I receptor inhibitors were also found to induce
differentiation of insulin-producing cells. Among the TGF-β
type I receptor inhibitors that we tested, Alk5 inhibitor II
showed unique effects on the differentiation of pancreatic
endocrine cells. Only Alk5 inhibitor II significantly increased
the expression of both INS and GCG, unlike the other TGF-β
type I receptor inhibitors (Fig. 4B and data not shown). In
the kinase profiling assay, Alk5 inhibitor II inhibited various ki-
nases at the concentration used in this study (data not
shown), suggesting that it might regulate the differentiation
of pancreatic endocrine cells by inhibiting various other sig-
nals in addition to those of TGF-β. The mechanisms involved
in differentiation of pancreatic progenitor cells into each
type of hormone-producing cell are largely unknown, so eluci-
dating the mechanism by which Alk5 inhibitor II acts would be
helpful for understanding the process of pancreatic endocrine
cell differentiation. Rezania et al. reported that insulin and
glucagon double-positive cells were induced by treatment
with Alk5 inhibitor II and that most of these cells finally differ-
entiated into glucagon-producing alpha cells (Rezania et al.,
2011). When pancreatic progenitor cells were treated with
Alk5 inhibitor II alone in our culture system, the percentage
of both glucagon-positive cells and glucagon and insulin
double-positive cells was relatively high (Fig. 4D), a finding
that was consistent with their results. However, when the
cells were treated with four compounds (forskolin, dexameth-
asone, Alk5 inhibitor II, and nicotinamide), induction of these
cells was much lower and most of the insulin-positive cells
that we obtained were also positive for PDX1(Figs. 4D, 5A,
and Fig. S5), which is not expressed in glucagon-producing
cells in the human fetal pancreas (Lyttle et al., 2008). More-
over, the number of insulin-positive (glucagon-negative)
282 Y. Kunisada et al.cells was much larger than that of glucagon-positive cells,
even after additional four weeks of culture (data not
shown). These results indicate that cells were more likely to
undergo differentiation into pancreatic β-cells by treatment
with the four compounds (forskolin, dexamethasone, Alk5 in-
hibitor II, and nicotinamide) in our culture system.
It is noteworthy that multiple hiPS cell lines showed dif-
ferentiation into insulin-producing cells by our protocol.
The hiPS cell lines that we utilized in this study were gener-
ated from the fibroblasts of various individuals, including a
neonatal male and a 73-year-old woman (Takahashi et al.,
2007; Nakagawa et al., 2008; Takahashi et al., 2009). Thus,
our results suggest that this is a robust protocol and that op-
timization for individual cell lines might not be required. In
another report, the rate of differentiation into insulin-
producing cells varied among different hES cell lines
(D'Amour et al., 2006). Since stable differentiation from var-
ious hiPS cell lines is necessary for clinical application, our
protocol could be beneficial for development of cell therapy
in the future.
Although this method was effective for inducing insulin-
producing cells, there are still several issues to be
addressed. First, the insulin-producing cells generated by
our protocol showed little insulin secretion in response to
glucose stimulation, and some of the cells co-expressed glu-
cagon or somatostatin, suggesting that the cells we obtained
were not fully functional mature β-cells. To induce the mat-
uration, further optimization of the culture condition seems
to be required. Second, the current protocol utilizes mouse
embryonic fibroblasts and FBS, but animal-derived sub-
stances are undesirable for clinical use. Third, this protocol
has not been applied to hES cells. Since hES cells are recog-
nized as the gold standard among pluripotent stem cells and
were utilized in many other studies, experiments on hES
cells would be useful for comparing our protocol with other
protocols and for improving our understanding the mecha-
nism of human pancreatic development.
In conclusion, we developed a simple method for promot-
ing the differentiation of hiPS cells into insulin-producing
cells. With this method, all of the hiPS cell lines that we
tested showed efficient differentiation into insulin-
producing cells, suggesting that our protocol achieves effi-
cient and reproducible generation of insulin-producing cells
in vitro. This protocol has the potential to contribute to
drug discovery and cell therapy for diabetes.Materials and methods
Cell culture
Human iPS cell lines (253G1, 201B7, 1503-iPS (297A1), 1392-
iPS (297F1), and NHDF-iPS (297L1)) were kindly provided by
the Center for iPS Cell Research and Application of Kyoto
University (Kyoto, Japan). The cells were maintained on
mitomycin-C treated-mouse embryonic fibroblasts (MEFs,
Oriental Yeast, Tokyo, Japan) in primate ES medium (Repro-
Cell, Tokyo, Japan) containing 4 ng/ml of human fibroblast
growth factor 2 (FGF2, ReproCell) and penicillin/streptomy-
cin (Invitrogen, Carlsbad, CA). Cells were passaged at
1:3–1:4 by using dissociation solution (ReproCell). Culture
was carried out at 37 °C under 5% CO2 in air.For pancreatic differentiation, hiPS cells were dissociated
with trypsin-EDTA, plated on MEFs at a density of
6.3×104 cells/cm2, and cultured for 24 h in primate ES medi-
um containing 10 μM Y-276342 (Wako, Osaka, Japan),
4 ng/ml FGF2, and penicillin/streptomycin. Then the cells
were cultured in primate ES medium containing 4 ng/ml FGF2
and penicillin/streptomycin for an additional 48 h. Next, the
cells were cultured in RPMI 1640 medium (Invitrogen) contain-
ing 2% fetal bovine serum (FBS, Invitrogen) with or without
100 ng/ml human activin A (PeproTech, Rocky Hill, NJ),
25 ng/ml mouse Wnt 3a (R&D, Minneapolis, MN), or 3 μM
CHIR99021 (Axon Medchem, Groningen, The Netherlands) for
24 h, and then in RPMI 1640 medium containing 2% FBS with
or without 100 ng/ml activin A for 48 h. Subsequently, the me-
dium was replaced with Improved MEM Zinc Option medium
(Invitrogen) containing 1% B27 (Invitrogen) with or without
100 ng/ml human Noggin (R&D), 1 μM dorsomorphin (Calbio-
chem, San Diego, CA), 2 μM retinoic acid (Sigma, St. Louis,
MO), or 10 μM SB431542 (Sigma). Cells were cultured for
seven days and then thesemedia were replaced with Improved
MEM Zinc Option medium supplemented with 1% B27. To en-
hance differentiation into insulin-producing cells, 10 μM for-
skolin (Wako), 10 μM dexamethasone (Wako), 5 μM Alk5
inhibitor II (Calbiochem), or 10 mM nicotinamide (StemCell
Technologies, Vancouver, BC) was added to the medium, and
two thirds of themediumwas replaced on every third or fourth
day of culture. The use of hiPS cells was approved by ethical re-
view committee of Takeda Pharmaceutical Company Limited.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
Total RNA was isolated from cells with an RNeasy 96 kit
(Qiagen, Valencia, CA), and cDNA was prepared with a Prime-
Script RT reagent kit (Takara Bio, Shiga, Japan) according to
the manufacturer's instructions. Quantitative RT-PCR analysis
was performed with the TaqMan system on a 7900HT Fast
Real-Time PCR analyzer (Applied Biosystems, Foster City,
CA). Primers and fluorogenic probes for RT-PCR are listed in
Supplementary Table 2. The reaction mixture consisted of
1×PlatinumQuantitative PCR SuperMix-UDGwith ROX (Invitro-
gen), 125 nM of the probe, 450 nM of the forward and reverse
primers, and template cDNA. To quantify PDX1 mRNA expres-
sion, a 0.5×probe and primer set (HS00236830, Applied Biosys-
tems) was utilized. Expression of each target gene was
normalized for the amount of total RNA or the level of glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) expression.
Human islets were obtained fromNational Disease Research In-
terchange (NDRI, PA, USA) through Human and Animal Bridging
(HAB) Research Organization (Chiba, Japan) following written
consent. The use of human islets was approved by ethical re-
view committee of Takeda Pharmaceutical Company Limited.
Immunostaining
Cells were fixed with 2% paraformaldehyde (PFA) for 10 min
and then with 4% PFA for 20 min at room temperature. After
washing with PBS, the cells were permeabilized and blocked
in PBS containing 0.1% Triton X-100 and 5% normal donkey
serum for 30 min at room temperature. Then the cells
283Insulin-producing cells from hiPS cellswere incubated overnight at 4 °C with the following primary
antibodies: goat anti-SOX17, 1:500 (AF1924, R&D); rabbit
anti-FOXA2, 1:100 (07-633, Millipore, Billerica, MA); goat
anti-PDX1, 1:200 or 1:400 (AF2419, R&D); guinea pig anti-
insulin, 1:500 (A0564, Dako); mouse anti-C-peptide, 1:1000
(MON5021, Sanbio, Uden, The Netherlands); goat anti-
glucagon, 1:400 (SC-7780, Santa Cruz Biotechnology, Santa
Cruz, CA); goat anti-ghrelin, 1:400 (SC-10368, Santa Cruz
Biotechnology); rabbit anti-somatostatin, 1:400 (A0566,
Dako); rabbit anti-PP, 1:50 (180043, Invitrogen); mouse
anti-PAX6, 1:100 (PAX6, Developmental Studies Hybridoma
Bank, Iowa City, IA); mouse anti-NKX2.2, 1:100 (74.5A5, De-
velopmental Studies Hybridoma Bank); goat anti-ISLET1,
1:100 (AF1837, R&D); and goat anti-NEUROD1, 1:100
(AF2746, R&D). After washing with PBS, the cells were incu-
bated for one hour at room temperature with Alexa Fluor
488- or 568-conjugated donkey or goat antibodies directed
against mouse, rabbit, goat, or guinea pig IgG at 1:500 dilu-
tions. For quantification, 15 images per well were obtained
using an IN Cell Analyzer 1000 (GE Healthcare, Buckingham-
shire, UK) and quantitative analysis was done with Developer
software (GE Healthcare).
Flow cytometry
Differentiated cells were dissociated with trypsin/EDTA,
fixed with 2% paraformaldehyde, and permeabilized with
BD Perm/Wash buffer (Becton Dickinson, Mountain View,
CA). The cells were incubated with mouse anti-C-peptide an-
tibody (1:1000, MON5021, Sanbio) and goat anti-glucagon
antibody (1:400, SC-7780, Santa Cruz Biotechnology) for
30 min at room temperature and then stained with Alexa
Fluor 488-conjugated donkey antibodies directed against
mouse IgG (1:500, Invitrogen) and Alexa Fluor 647-
conjugated donkey antibodies directed against goat IgG
(1:500, Invitrogen) for 30 min at room temperature. Flow
cytometry was done with a FACScalibur (Becton Dickinson)
or a FACSAria II (Becton Dickinson).
C-peptide release assay
Differentiated cells were preincubated for 2 h at 37 °C in
Krebs-Ringer bicarbonate HEPES buffer (KRBH; 116 mM
NaCl, 4.7 mM KCl, 2.5 mM CaCl2 1.2 mM KH2PO4, 1.2 mM
MgSO4, 24 mM HEPES, 25 mM NaHCO3, and 0.1% BSA) con-
taining 2.5 mM glucose. Then, the cells were incubated for
1 h at 37 °C in KRBH containing the indicated concentrations
of glucose or stimulants, including 2 μM (−)-Bay K8644,
100 μM tolbutamide, 250 μM carbachol, 0.5 mM IBMX, or
30 mM potassium chloride (KCl). C-peptide was measured
with a human C-peptide ELISA kit (Mercodia AB, Uppsala,
Sweden) according to the manufacturer's instructions.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.10.002.
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